UTHR UNITED THERAPEUTICS CORP DEL revenue, earnings and financials

For the quarter ended June 30, 2026, UNITED THERAPEUTICS CORP DEL reported revenue of $783M (down 1.9% from a year earlier), net income of $333M and diluted EPS of $7.27; over the last four quarters revenue was $3.15B and net income $1.31B; for the fiscal year ended December 2025 revenue was $3.18B, up 10.6% on the year before.

UTHR annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $3.18B, gross profit $2.80B, operating income $1.49B, net income $1.33B (margin 41.9%), EPS $27.86
• Fiscal year ended Dec 2024: revenue $2.88B, gross profit $2.57B, operating income $1.38B, net income $1.20B (margin 41.5%), EPS $24.64
• Fiscal year ended Dec 2023: revenue $2.33B, gross profit $2.07B, operating income $1.18B, net income $985M (margin 42.3%), EPS $19.81
• Fiscal year ended Dec 2022: revenue $1.94B, gross profit $1.78B, operating income $980M, net income $727M (margin 37.6%), EPS $15.00
• Fiscal year ended Dec 2021: revenue $1.69B, gross profit $1.56B, operating income $556M, net income $476M (margin 28.2%), EPS $10.06

UTHR quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $783M (down 1.9% year over year), net income $333M, EPS $7.27
• Quarter ended Mar 31, 2026: revenue $782M (down 1.6% year over year), net income $275M, EPS $5.82
• Quarter ended Dec 31, 2025 (from the annual report): revenue $790M (up 7.4% year over year), net income $364M, EPS $7.66
• Quarter ended Sep 30, 2025: revenue $800M (up 6.8% year over year), net income $339M, EPS $7.16
• Quarter ended Jun 30, 2025: revenue $799M (up 11.7% year over year), net income $310M, EPS $6.41
• Quarter ended Mar 31, 2025: revenue $794M (up 17.2% year over year), net income $322M, EPS $6.63
• Quarter ended Dec 31, 2024 (from the annual report): revenue $736M (up 19.7% year over year), net income $301M, EPS $6.23
• Quarter ended Sep 30, 2024: revenue $749M (up 22.9% year over year), net income $309M, EPS $6.39
• Quarter ended Jun 30, 2024: revenue $715M (up 19.8% year over year), net income $278M, EPS $5.85
• Quarter ended Mar 31, 2024: revenue $678M (up 33.7% year over year), net income $307M, EPS $6.17
• Quarter ended Dec 31, 2023 (from the annual report): revenue $615M (up 25.1% year over year), net income $217M, EPS $4.33
• Quarter ended Sep 30, 2023: revenue $609M (up 18.1% year over year), net income $268M, EPS $5.38
• Quarter ended Jun 30, 2023: revenue $597M (up 27.8% year over year), net income $259M, EPS $5.24
• Quarter ended Mar 31, 2023: revenue $507M (up 9.7% year over year), net income $241M, EPS $4.86
• Quarter ended Dec 31, 2022 (from the annual report): revenue $492M (up 18.4% year over year), net income $132M, EPS $2.65
• Quarter ended Sep 30, 2022: revenue $516M (up 16.0% year over year), net income $239M, EPS $4.91
• Quarter ended Jun 30, 2022: revenue $467M (up 4.6% year over year), net income $116M, EPS $2.41
• Quarter ended Mar 31, 2022: revenue $462M (up 21.8% year over year), net income $240M, EPS $5.03
• Quarter ended Dec 31, 2021 (from the annual report): revenue $415M, net income $112M, EPS $2.38
• Quarter ended Sep 30, 2021: revenue $445M, net income $163M, EPS $3.42

UTHR cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $1.56B, share buybacks $1.00B
• Fiscal year ended Dec 2024: operating cash flow $1.33B, share buybacks $1.00B
• Fiscal year ended Dec 2023: operating cash flow $978M, share buybacks $0
• Fiscal year ended Dec 2022: operating cash flow $803M, share buybacks $0
• Fiscal year ended Dec 2021: operating cash flow $598M, share buybacks n/a

UTHR balance sheet

• Jun 30, 2026: cash $1.80B, total assets $7.22B, total liabilities $820M, shareholders' equity $6.40B
• Mar 31, 2026: cash $1.28B, total assets $6.71B, total liabilities $813M, shareholders' equity $5.90B
• Dec 31, 2025: cash $1.56B, total assets $7.88B, total liabilities $784M, shareholders' equity $7.10B
• Sep 30, 2025: cash $1.34B, total assets $7.35B, total liabilities $761M, shareholders' equity $6.59B
• Jun 30, 2025: cash $1.59B, total assets $7.91B, total liabilities $734M, shareholders' equity $7.17B
• Mar 31, 2025: cash $1.90B, total assets $7.74B, total liabilities $937M, shareholders' equity $6.81B
• Dec 31, 2024: cash $1.70B, total assets $7.36B, total liabilities $920M, shareholders' equity $6.44B
• Sep 30, 2024: cash $1.55B, total assets $7.12B, total liabilities $1.02B, shareholders' equity $6.10B

What is UTHR's revenue?

UNITED THERAPEUTICS CORP DEL reported $3.15B of revenue over its last four quarters, through June 30, 2026.

Is UTHR profitable?

Yes. UNITED THERAPEUTICS CORP DEL earned $1.31B over the last four quarters.

What is UTHR's EPS?

Diluted earnings per share over the last four quarters were $27.91; $7.27 in the latest quarter.

UTHR ownership and insider trades · All stocks